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Clinical and Pathological Features of Microscopic
Polyangiitis in 20 Children
Liangzhong Sun, Haiyan Wang, Xiaoyun Jiang, Ying Mo, Zhihui Yue, Liuyi Huang, 
and Ting Liu
ABSTRACT. Objective. To explore the clinical and pathological features of microscopic polyangiitis (MPA) in
children.
Methods.A retrospective analysis was performed of patients with pediatric MPA in our hospital over
10 years.
Results. Data for 20 patients were collected; 16 patients had primary MPA (4 boys, 12 girls), with a
median age of 8.9 years at the time of disease onset; 4 patients, all female, had antithyroid drug
(ATD)-associated MPA, with an age range of 12.5 to 16.2 years at the time of disease onset. All
patients exhibited renal involvement. Renal biopsies were performed in 14 patients. Fibrinoid
exudation and necrosis of the glomerular capillaries were observed in all biopsy specimens.
Crescents and scleroses were noted in 92.9% and 85.7% of these cases, respectively. The most
frequent extrarenal organs involved were lungs, followed by the central nervous system (CNS), skin,
and digestive system. Ninety percent of patients were positive for perinuclear antineutrophil
cytoplasmic antibody, 94.1% were positive for myeloperoxidase, and 88.2% were positive for both.
Forty-five percent of the patients had received steroid plus cyclophosphamide (CTX) pulse therapy
for more than 3 months, and varying degrees of remission had been achieved in 88.9% of the
patients. 
Conclusion. Both primary and ATD-associated MPA showed a female predisposition. Renal
involvement was the most frequently observed condition, followed by involvement of lungs. CNS
involvement was not rare in these pediatric patients. The efficacy of steroid plus CTX as induction
therapy was evident in these patients. (First Release July 1, 2014; J Rheumatol 2014;41:1712–19;
doi:10.3899/jrheum.131300)
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Microscopic polyangiitis (MPA) is a small-vessel vasculitis
associated with antineutrophil cytoplasmic antibody
(ANCA)1. MPA typically exhibits multiple organ involve-
ment, affecting kidneys, lungs, skin, gastrointestinal tract,
and the nervous system. MPA can be divided into primary
and secondary forms based on its causative factor. The latter
form is primarily caused by treatment with antithyroid drugs
(ATD), particularly propylthiouracil (PTU)2. MPA rarely
occurs in children3.
MATERIALS AND METHODS
Children with MPA who were treated in our hospital between 2003 and
2013 were evaluated in our study. The diagnosis of primary MPA was based
on the 2012 revised Chapel Hill Consensus Conference Nomenclature of
Vasculitides1, and ATD-associated MPA has been defined4. Renal
involvement was defined by hematuria (≥ 3 red blood cells/high-power
field) and proteinuria (> 150 mg/day)5.
Definitions. Renal insufficiency was diagnosed as described6. Chronic
kidney disease (CKD) was defined using Kidney Disease Outcomes
Quality Initiative staging (stage 1 to 5)7, and glomerular filtration rate was
calculated according to the Schwartz formula8. We defined hypertension
(HTN) as office-measured systolic or diastolic blood pressure ≥ 95th
percentile for sex, age, and height, according to international guidelines9.
The grade of proteinuria was classified as mild to moderate proteinuria 
(< 50 mg/kg/24 h) or severe proteinuria (nephrotic range, ≥ 50 mg/kg/24 h).
Disease activity was scored according to the Birmingham Vasculitis
Activity Score (BVAS)10. Irreversible damage was assessed using the
Vasculitis Damage Index (VDI)11.
Treatment protocols4. Induction therapy consisted of a corticosteroid
(prednisone: 1–2 mg/kg/day, tapered gradually at 4–8 weeks) plus cyclo-
phosphamide (CTX: 0.75 g/m2/month for 6 mos). For patients with severe
organ involvement [pulmonary hemorrhage, rapidly progressive glomeru-
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lonephritis, digestive tract hemorrhage, central nervous system (CNS)
involvement], methylprednisolone pulse therapy (7.5–15 mg/kg qod, 3 to 6
administrations per course) was initially used, followed by prednisone plus
CTX. 
Maintenance therapy consisted of low-dose corticosteroid (prednisone:
5–10 mg/day) plus CTX (0.5–0.75 g/m2 every 3 mos) pulse therapy. If CTX
was not tolerated or not accepted, mycophenolate mofetil [MMF
(CellCept): 20–30 mg/kg/day/bid] was used as a substitute. The patients
received maintenance therapy for 1 to 2 years12.
Calcium ion antagonists (nifedipine) were the baseline antihypertension
medication. Angiotensin converting enzyme inhibitors (ACEI), such as
enalapril, benazepril, and fosinopril; b-receptor antagonists (metoprolol),
and a-receptor antagonists (terazosin) were used when HTN could not be
controlled by the baseline drug. Antiproteinuric treatment using ACEI was
indicated in patients who did not achieve complete remission and whose
renal function was not at CKD stage 5.
Treatment response. Definitions of complete remission (CR), partial
remission (PR), treatment failure, and relapse were as reported13,14.
Damage was assessed according to VDI at the last followup visit if the
patients were monitored for more than 3 months.
RESULTS
General data (Table 1). Twenty children (4 boys, 16 girls)
were evaluated. For 14 patients, the diagnoses were evident
from the patients’ renal biopsies. Renal biopsies were not
performed in the remaining 6 patients (5 patients with
primary MPA, 1 patient with secondary MPA); the
diagnoses were based on the clinical manifestations and the
serological changes in their disease15. Granuloma and
autoimmune diseases were excluded. 
Sixteen of the 20 patients (4 boys, 12 girls) had primary
MPA, with a median age of 8.9 years (1.9–16.8 yrs) at
disease onset. The median disease course (before diagnosis)
was 4 months (0.1–42 mos). The remaining 4 patients with
secondary MPA were female, and the age at disease onset
ranged from 12.5 to 16.2 years, with disease courses of
about 1 month. The duration of PTU administration was 7
months to 6 years. Patient 19 had received PTU and methi-
mazole (MMI) from the time of her hyperthyroidism
diagnosis. PTU was discontinued 8 months after improve-
ment in hyperthyroidism, whereas MMI administration
continued for an additional 2 years until renal impairment
was noted. Moreover, her dizygotic twin sister, diagnosed
with hyperthyroidism at the same time, received the same
treatment regimen. However, the sister had normal routine
urinary test results, normal renal function, and normal levels
of perinuclear ANCA (pANCA), cytoplasmic ANCA
(cANCA), myeloperoxidase (MPO), and proteinase 3.
Clinical and renal pathological features (Tables 1, 2, and 3).
Ninety percent (18/20) of the patients (14 patients with
primary MPA and 4 patients with secondary MPA) pre-
sented with normocytic normochromic anemia; 2 patients
had mild anemia with hemoglobin (Hb) ≥ 90 g/l, 14 patients
had moderate anemia with Hb 60–90 g/l, and 2 patients had
severe anemia with Hb < 60 g/l. Fifty percent (10/20) of the
patients (8 patients with primary MPA, and 2 patients with
secondary MPA) presented with irregular fever during the
early disease course without apparent infection. The median
BVAS in all patients was 14.5 (range, 8–28).
Renal involvement was observed in all 20 patients.
Eighty-five percent of all patients (17/20) presented with
hematuria and proteinuria; gross hematuria was noted in
only 2 patients, and 2 mild cases with isolated hematuria
were observed. Fifty-two percent of patients (9/17) showed
mild to moderate proteinuria; in 47% of patients (8/17),
proteinuria reached a nephrotic range, and 6 patients
exhibited signs of nephrotic syndrome. At the time of
diagnosis, renal insufficiency was observed in 60% of the
patients (12/20), HTN was observed in 45% (9/20), and
rapidly progressive glomerulonephritis was observed in
40% (8/20).
Renal biopsies were obtained from 14 patients (Table 3).
Crescents were observed in the renal specimens of 92.9% of
the patients (13/14). All biopsied patients showed glomeru-
lar fibrinoid exudation and glomerular necrosis. Segmental
or global glomerular sclerosis was observed in 85.7% of
biopsies (12/14). Small amounts of deposits of nonspecific
immune complex (IC) were observed in 71.4% of the
biopsies (10/14). These deposits typically showed a
segmental deposition of IgM and C3. Small amounts of
focal IgA deposits were noted in the mesangial area in 2
patients. In the 3 patients with secondary MPA, no IC
deposits were noted. Inflammatory cell infiltration and inter-
stitial fibrosis were noted in 71.4% (10/14) and 42.9%
(6/14) of the patients, respectively.
Of the 20 patients with MPA, 60% (12/20) showed
involvement of more than 1 extrarenal organ. Fifteen
percent (3/20) exhibited lung involvement; 3 patients with
primary MPA presented with coughing and hemoptysis
sputum. The other patient had secondary MPA and
presented with coughing and tachypnea; however, her chest
radiograph was normal. Fifteen percent (3/20) of patients (1
primary MPA, 2 secondary MPA) showed CNS symptoms,
including headaches, convulsions, and symptomatic epil-
epsy. Cerebral edema, cerebral vasculitis, and focal
ischemia were subsequently exhibited on magnetic reson-
ance imaging scans (Figure 1A and 1B). Fifteen percent of
the patients (3/20) showed skin involvement; their clinical
manifestations included ulcers, necrosis, petechiae, and
pinpoint red rash, all of which were present in the lower
limbs. Fifteen percent (3/20) of the patients, all of whom
had primary MPA, showed digestive system symptoms. One
patient showed a recurrent hemorrhage of the lower
digestive tract; a colonoscopy revealed ulcers and hemor-
rhaging in the splenic flexure and sigmoid colon. Patho-
logical examination revealed chronic colorectal inflam-
mation with ulcers. The other 2 patients who presented with
abdominal pain had duodenal ulcers and chronic congestive
exudative gastritis with antral erosion. In addition to organ
involvement, myalgia, arthritis, and eye involvement were
observed separately in 1 patient with primary MPA.
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ANCA and other laboratory results (Table 2). Positive
pANCA results were observed in 90% of patients (18/20),
and 94.1% of patients (16/17) analyzed were positive for
MPO. Positive results for both pANCA and MPO were
observed in 88.2% (15/17) of patients analyzed [84.6%
(11/13) of primary MPA cases, 100% (4/4) of secondary
MPA cases]. 
Sixty-three percent of the patients tested (12/19) were
positive for ANA (8 patients with primary MPA and 4
patients with secondary MPA), whereas 42.1% of the
patients tested (8/19) were positive for both ANA and
dsDNA. Seventy-five percent (15/20) had normal comple-
ment 3 (C3) levels, and 1 (patient 1) had an elevated C3
level. Four patients showed decreased C3 levels (3 patients
with primary MPA and 1 patient with secondary MPA); of
those 4 patients, 3 were negative for both ANA and dsDNA,
and 1 (patient 20) was ANA-positive but dsDNA-negative.
Ninety-five percent of patients tested (18/19) showed
increased erythrocyte sedimentation rates (ESR). Apart
from those with infections, 61.1% of tested patients (11/18)
had normal ranges of serum C-reactive protein (CRP)
levels; elevated CRP levels were observed in 38.9% of the
patients (7/18), and 3 patients had only mildly elevated CRP
levels.
Table 1. Summary of clinical features of microscopic polyangiitis in 20 children.
Patient Sex Onset Disease uRBC/ Main GFR at BVAS Immuno- Antihyper- Antiprotein- Time VDI Prognosis
Age, Course, uPro Manifestations Diagnosis suppressive tensive uric of   
yrs mos Therapy Therapy Therapy Followup,
mos
1 F 10.0 12 +/+ Fever, anemia, RI 15.4 13 CTX, MP, P — No Lost — CKD 4
2 F 14.3 2 +/+ Anemia 95.4 12 CTX, MP, P — No Lost — Lost
3 F 10.3 5 +/+ Anemia, arthralgia, 107.0 9 CTX, MP, P — No 78 0 CR
gastrointestinal hemorrhage
4 F 3.0 42 +/+ Fever, anemia, HTN, 49.0 17 CTX, MP, P Yes Yes 58 1 CKD 3 (PR)
RI, hemoptysis sputum
5 F 8.3 8 +/+ Anemia, photophobia, 156.1 18 CTX, MP, P — No 31 1 Initially CR, 
blurred vision, corneal but progressed 
ulcer, myalgia to CKD 5 
eventually
6 M 7.6 24 +/+ Anemia, HTN, RI, 5.18 16 N Yes No 4 1 CKD 5
necrotic skin ulcers
7 F 16.0 1 +/+ Anemia, HTN, 121.7 15 CTX, MP, P No No 8 0 CR
duodenal ulcer
8 F 12.1 3 +/+ Fever, anemia, HTN,  9.3 22 CTX, MP, P, Yes No 16 2 CKD 5 (PR)
RI, alimentary tract then renal 
hemorrhage transplantation
9 F 8.5 0.5 +/+ Anemia, HTN, 7.5 27 N Yes No 4 2 CKD 5, died
RI, convulsion
10 F 1.9 12 +/+ Fever, anemia, 58.8 23 CTX, MP, — No 10 0 CR
hemoptysis sputum P, MMF
11 M 8.8 6 +/+ Fever, anemia, 13 28 N Yes No 12 2 CKD 5
HTN, RI, rashes
12 F 5 3 +/+ Fever, anemia, RI 9.6 13 N — No Lost — CKD 5
13 F 2.8 0.5 +/– Fever 139.7 9 N — No 10 — SR
14 M 3.6 18 +/– None 165.7 8 N — No Lost — SR
15 F 10.3 18 +/+ Anemia, HTN, RI 10.9 12 N No No Lost — CKD 5
16 M 16.8 1 +/+ Anemia, HTN, RI 24.9 12 N No No Lost — CKD 4
17 F 12.5 1 +/+ Fever, anemia, 49.4 14 CTX, MP, P — Yes 79 0 CR
RI, rashes
18 F 16.2 1 +/+ Anemia, tachypnea 104.9 14 CTX, MP, P — No Lost — Lost
19 F 13.8 1 +/+ Fever, anemia, HTN, 12.9 25 CTX, MP, P, PE Yes No 12 2 CKD 5 (PR), 
RI, dizziness, convulsion died
20 F 13.3 1 +/+ Fever, anemia, 18.5 25 CTX, MP, — No 4 2 CKD 4, died
RI, convulsion PE, IVIG
BVAS: Birmingham Vasculitis Activity Score (at time of diagnosis); CKD: chronic kidney disease; CNS: central nervous system; CR: complete remission;
CrGN: crescentic glomerulonephritis; CTX: cyclophosphamide; GFR: glomerular filtration rate; HTN: hypertension; IVIG: intravenous immunoglobulin;
MMF: mycophenolate mofetil; MMI: methimazole; MP: methylprednisolone; N: no specific therapy; P: prednisone; PE: plasma exchange; PR: partial
remission; RI: renal insufficiency; SR: spontaneous remission; uPro: urine protein; uRBC: uric red blood cells; VDI: Vasculitis Damage Index; +: positive;
–: negative.
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Treatment and prognosis (Table 1). Of the 16 patients with
primary MPA, 37.5% (6/16) received steroid plus CTX
pulse therapy for more than 3 months and achieved varying
degrees of remission, 4 patients (patients 3, 5, 7, and 10)
achieved CR; their routine urine tests returned to normal
after 3 months, 2 months, 3 months, and 8 months of
Table 2. Summary of laboratory tests for microscopic polyangiitis in children.
Patient p-ANCA/c-ANCA/ ANA/dsDNA C3 ESR CRP 
MPO/PR3 (0.77–1.95 g/l) (≤ 20 mm/h) (≤ 3 mg/l)
1 +/–/ND/ND +/– 2.25 128 2.21
2 +/–/+/– –/– 1.04 27 4.8
3 +/–/+/– –/– 1.43 44 5.8
4 +/–/+/– +/+ 0.94 28 1.0
5 +/–/+/– +/+ 1.35 33 8.32
6 +/–/+/– +/+ 0.9 41 ND
7 –/+/–/+ –/– 0.73 19 32.5
8 +/–/+/+ +/+ 1.0 46 1.79
9 +/–/+/– –/– 0.86 45 2.22
10 +/–/+/– +/+ 0.91 15 < 1
11 +/–/+/– +/– 0.9 76 2.7
12 +/–/+/– +/+ 1.1 36 2.53
13 +/–/+/– –/– 0.25 8 < 1
14 –/+/+/– –/– 0.69 ND 0.73
15 +/–/ND/ND –/– 1.26 105 ND
16 +/–/ND/ND ND 1.42 108 10.9
17 +/–/+/– +/– 1.23 90 43.3
18 +/–/+/– +/+ 0.9 40 4.29
19 +/–/+/– +/+ 0.81 53 < 1
20 +/–/+/– +/– 0.63 24 2.3
ANA: antinuclear antibody; CRP: C-reactive protein; C3: complement 3; ESR: erythrocyte sedimentation rate;
ND: not detected; +: positive; –: negative; MPO: myeloperoxidase; p-/c-ANCA: perinuclear/cytoplasmic
antineutrophil cytoplasmic antibodies.
Table 3. Renal pathological features of 14 patients who underwent biopsies to diagnose microscopic polyangiitis (MPA).
Patient No. No. Cellular Fibrocellular Fibrous No. Fibrinoid Immune Interstitial Pathology 
Glomeruli Crescents Crescents Crescents Crescents Sclerotic Exudation Complex Fibrosis/ Diagnosis
Glomeruli or Necrosis Inflammation
1 9 3 3 0 0 6 Yes IgA+~++, C3++, Yes/Yes Necrotic glomerulonephritis
focal segmental
2 7 4 4 0 0 0 Yes IgA+, IgM±, C3± No/Yes Crescentic glomerulonephritis
3 26 2 2 0 0 2 Yes IgM±~+ Yes/Yes Necrotic glomerulonephritis
4 24 1 1 0 0 13 Yes IgM++, C4+ Yes/No Proliferative and sclerotic 
glomerulonephritis
5 29 4 0 2 2 0 Yes – No/Yes Focal segmental glomerular 
necrosis with crescents
6 44 2 1 1 0 40 Yes C3+, C1q+ Yes/Yes Sclerotic glomerulonephritis
7 50 5 4 1 0 3 Yes IgM+ No/Yes Focal segmental glomerular 
necrosis with crescents
8 7 0 0 0 0 5 Yes C3+ Yes/Yes Proliferative and sclerotic 
glomerulonephritis
9 9 5 1 4 0 5 Yes – No/Yes Crescentic glomerulonephritis
10 47 15 1 13 1 0 Yes IgM+ Yes/Yes Focal segmental glomerular 
necrosis with crescents
11 23 5 0 0 5 3 Yes IgA+, IgG+ No/Yes MPA
17 23 2 2 0 0 18 Yes – No/Yes Proliferative and sclerotic 
glomerulonephritis
18 19 5 0 5 0 1 Yes – No/Yes MPA
19 20 12 3 8 1 8 Yes – No/Yes Crescentic glomerulonephritis
–: negative; ±: trace; +: mild; ++: moderate.
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treatment, respectively. Hb levels returned to normal, and
sera samples were pANCA-negative after 11 months for
patient 3 and after 8 months for patient 10. ANCA was not
reexamined for patient 5. The gastrointestinal ulcer in
patient 7 improved; the patient became ANCA-negative at 4
months after treatment, and routine urine tests were normal
after 1.5 years of treatment. In patient 3, the initial renal
pathological change noted was focal necrotic glomeru-
lonephritis with crescents. At 1 year after treatment, a repeat
renal biopsy revealed minimal change in disease, with focal
glomerular sclerosis. The patient was followed up for 6.5
years; an occasional relapse was observed, with mild urinary
changes (red blood cell-positive, protein-negative). Although
CR was achieved in patient 5 after inductive treatment, she
progressed to CKD stage 5 after 2 years and 7 months.
MMF with low-dose prednisone was used for maintenance
therapy after 6 months of inductive therapy for patient 10;
this patient achieved CR by the eighth month of treatment.
However, hemoptysis, hematuria, and proteinuria were
recurrent during maintenance therapy, and CR was again
achieved after MP pulse therapy. PR was observed in 2
patients (patients 4 and 8), and the VDI scores were 1 for
patient 4 and 2 for patient 8. In patient 4, extrarenal symptoms
were ameliorated, and the patient became ANCA-negative
at 10 months after treatment, whereas the renal function and
urinary sediment levels did not return to normal levels
(CKD stage 3, urine protein-positive). All gastrointestinal
symptoms, hematuria, and proteinuria disappeared in patient
8 after the treatment regimen; however, her renal function
did not recover. She subsequently underwent renal trans-
plantation and recovered well afterward. Of the patients
with primary MPA, 62.5% (10/16) did not follow the default
treatment: 2 patients progressed to CKD stage 4; 5 patients
progressed to CKD stage 5; and 2 patients, whose clinical
manifestations were mild with only isolated hematuria and
who had no extrarenal organ involvement, recovered
spontaneously without any specific treatment; the remaining
1 patient was lost to followup.
For the 4 patients with secondary MPA, ATD was discon-
tinued, and corticosteroid plus CTX treatment was adminis-
Figure 1. Comparison of encephalic lesions before and after treatment in patient 19. A. Coronal brain magnetic resonance image (MRI)
before treatment, on which an abnormal signal of ischemia was observed in the parietal cortex and subcortical white areas (arrow). 
B. Coronal brain MRI image after treatment showing that the area of the ischemic lesion apparently recovered (arrow).
Figure 2. Renal histology of patient 19 (A, B, C: periodic acid-Schiff staining; original magnification of A, B: ×200; C: ×400). Cellular
crescents, fibrocellular crescents, and fibrous crescents coexisted in the same patient. A. Globe glomerular sclerosis, a fibrous crescent
(arrow), and lymphocytic infiltration in the interstitial space. B. A fibrocellular crescent (arrow), atrophy of the renal tubers, and inter-
stitial fibrosis. C. Fibrinoid necrosis and a fibrous crescent (arrow). Bar: A and B: 60 µm; C: 30 µm. 
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tered after diagnosis of MPA. Three subjects (patients 17,
19, 20) were treated for more than 3 months. Patient 17 had
mildly impaired renal function at the time of admission.
That patient’s pANCA and MPO levels became negative,
and CR was achieved 7 months and 14 months after treat-
ment, respectively. However, pANCA, MPO, and urinary
sediment tests were occasionally positive during main-
tenance therapy. Patient 19 was in acute renal failure when
she was admitted. Plasma exchange was administered
during the earlier treatment. ANCA disappeared at 2 months
after the treatment regimen, CNS symptoms were relieved,
and cerebrovascular inflammation and cerebral ischemia
also improved (Figure 1). However, the hematuria, protein-
uria, and renal insufficiency remained. The patient acquired
a severe infection (pneumonia and septicemia) during
induction treatment and died 1 year later from a pulmonary
infection. Patient 20 was in CKD stage 5 when she was
admitted to the hospital. She had pneumonia during the
course of induction treatment and died 4 months after
admission because of her poor physical condition. Patients
19 and 20 had VDI scores of 2 before death. Patient 18 had
mildly impaired renal function and was lost to followup at 1
month after treatment.
Six of the 9 patients with HTN received antihypertensive
therapy. Two of 4 patients (patients 4, 16, 17 and 20) who
had not achieved CR and whose renal function was not at
CKD stage 5 received antiproteinuric treatment (Table 1).
In total, 7 patients were lost to followup; 13 patients had
been followed up for 4–9 months, and 9 of these 13 patients
received corticosteroid plus CTX therapy for more than 3
months: 88.9% (8/9) achieved varying degrees of remission,
55.6% (5/9) achieved CR, and 33.3% (3/9) progressed to
CKD stage 3 to 5, and the remaining 1 patient died. Of the
11 patients who received immunosuppressive medication, 2
(patients 19 and 20) were severely infected during induction
therapy, and both died subsequently. Longterm side effects,
such as impairment of fertility and tumorigenesis, were not
observed in our study. Fifty-five percent (11/20) of all
patients progressed to CKD stage 4, CKD stage 5, or death.
Moreover, the BVAS was reassessed after induction
treatment; the BVAS were 0 in all 5 patients who achieved
CR, ranging from 8 to 12 in 3 patients with CKD. The VDI
scores were 0 in all patients who achieved CR, and they
ranged from 1 to 2 in patients with CKD or those who died
(Table 1).
DISCUSSION
According to the literature, MPA is the most frequent form
of ANCA-associated vasculitis in children, although the
incidence of granulomatosis with polyangiitis in adults is
higher than that of MPA in northern Europe16,17. MPA
occurs more frequently in female subjects, and the mean age
at the time of onset in children is 10 to 12 years3,13,18.
Compared with adult MPA, there is a lower prevalence of
HTN and a higher incidence of acute renal failure and
CKD18. In our present study, most patients (80%) were
female. Of the patients with primary MPA, 75% were
female, with a median age of 8.9 years at the time of disease
onset. All 4 patients with secondary MPA were female, with
an age range of 12.5 to 16.2 years.
The kidneys are the most frequent organ involved in
MPA in children and adults3; hematuria and proteinuria are
the primary manifestations14. In our current study, all
patients showed renal involvement, and the majority
presented with both hematuria and proteinuria. Mild to
moderate proteinuria was frequently noted. However, only a
few patients fulfilled the criteria for nephrotic syndrome.
These results were similar to those in adults19. In the present
study, renal insufficiency and HTN at the time of diagnosis
were not rare, and the majority showed varying degrees of
renal interstitial fibrosis, which is an indicator of chronic
kidney disease. These data suggested that early diagnosis of
MPA in children is difficult and has not yet been achieved in
this field of study.
The typical renal histopathology of MPA is pauciimmune
glomerulonephritis with glomerular capillary necrosis and
crescent formation20. In our present study, typical vasculitis
lesions were evident in all of the patients biopsied.
Crescents were also evident in the majority of the patients.
Another distinctive pathological feature of MPA is the
presence of different phases of renal lesions, such as cellular
crescents, fibrocellular crescents, and fibrous crescents,
which can coexist in the same biopsy specimen (Figure 2).
Although MPA is a pauciimmune glomerulonephritis, small
amounts of nonspecific IC have been found in many
patients. Yu, et al4,5 reported that IC of IgM, IgG, IgA, C3,
and C1q was present in 65% of patients with primary MPA
and 60% of patients with PTU-associated MPA. In the
present study, we found small amounts of nonspecific IgM,
IgA, C3, and C1q deposits in the glomeruli of many patients
with primary MPA; however, IC deposits were not observed
in the glomeruli of 3 patients with secondary MPA.
Fever and anemia have been commonly noted in patients
with MPA3. Consistent with the literature21, 50% of our
patients presented with irregular fever, and the majority
showed varying degrees of anemia. Extrarenal organ(s)
involvement was observed in the majority of patients. Lung
involvement reportedly occurs in 19.0% of patients with
MPA, followed by involvement of the skin, joints, and so
on22. Pulmonary involvement was also frequent in our group
of patients. Surprisingly, CNS involvement, which has
seldom been observed in other studies, was noted in 15% of
our patients. Further studies are required to determine
whether CNS involvement occurs more frequently in
children with MPA (particularly in ATD-associated MPA).
ANCA are specific hallmarks used for diagnosing
vasculitis23, and pANCA is more specific for MPA.
Bakkaloglu, et al24 reported that the specificity of a diagnosis
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of MPA based on the patient being both pANCA- and
MPO-positive was 99%. In our present study, patients who
were positive for both pANCA and MPO comprised 88.2%
of the tested patients. According to the literature, titers of
ANCA decreased to normal levels after treatment in 28.6%
of patients with MPA25, and ANCA could be used as an
index for assessing MPA relapse25,26. These changes were
noted in our study. ANCA were negative in the majority of
patients who achieved varying degrees of remission after
treatment. Two patients became ANCA-positive during
relapse.
With regard to other immunological disorders, we noted
that most of our tested patients were ANA-positive, and
about 40% were both ANA and dsDNA-positive. Of the
ATD-associated patients with MPA, all were ANA-positive
and 2 were dsDNA-positive; and 1 patient had a low C3
serum level. These data suggest that the differential
diagnosis from systemic lupus erythematosus can be
challenging. It has been reported that increased ESR is
associated with reduced survival in patients with MPA22.
However, in our present study, an increased ESR was
observed in the majority of patients, and their levels
returned to normal during remission. In our present study,
C3 levels were normal in the majority, and most of the
patients had normal or only mildly elevated serum CRP
levels. Relationships between disease activity and C3 levels
and CRP levels were not observed. 
The clinical and pathological features of ATD-associated
MPA are similar to those of primary MPA25. We also saw
these in our study. PTU is the primary medication that
induces MPA. MMI-associated MPA typically shows mild
manifestations27. In our present study, in patient 19, MPA
symptoms were observed 2 years after PTU was discon-
tinued, whereas MMI was taken continuously. Unfortun-
ately, urinary test and renal function were not monitored
during her treatment for hyperthyroidism. PTU-associated
MPA typically regressed after ATD withdrawal, and
MMI-associated MPA should be noted in this child. Fresh
crescents were observed in her kidney biopsy, which further
supported this hypothesis. However, the clinical manifesta-
tions appeared to be too severe for MMI-associated MPA.
Thus, the contribution of PTU to the pathogenesis of MPA
in this child should also be considered. Moreover, there
might be synergistic pathogenesis between PTU and MMI.
Interestingly, patient 19 had a dizygotic twin sister who had
similarly been treated with PTU and MMI for hyper-
thyroidism. However, she showed no signs of MPA, which
indicated that the genetic background may not play an
important role in the pathogenesis of MPA.
Early diagnosis and early and standard treatment are key
factors for improving MPA prognosis14. Steroid plus
cytotoxic agents constitute effective therapy for MPA28. In
our present study, early diagnosis was not achieved in some
patients, as shown by the renal pathological changes.
Although most of the treated patients responded to induction
therapy, more than 50% of the children progressed to late
CKD stages, including 1 patient who achieved CR initially,
but then progressed to CKD 5 in the end. These results
might be attributed to the delayed diagnosis and treatment
and/or to unoptimized treatment. It has been reported that an
initial favorable response to immunosuppressive therapy
might not necessarily prevent the occurrence of renal scar-
ring29. Therefore, regular followup is important for improv-
ing prognosis. It was a pity that quite a few patients were
lost to followup in our study. Nonimmunological interven-
tions, such as antihypertensive and antiproteinuric treat-
ments, are also important in slowing progression of kidney
injury. Regretfully, these interventions were not adminis-
tered in several patients in our present study, which could be
attributed to the progression to late CKD stages in those
patients.
Fujieda, et al25 reported that patients with PTU-induced
MPA showed milder manifestations of disease and better
prognoses than patients with primary MPA. In the present
study, the prognosis of ATD-associated MPA was not better
than that of primary MPA, which could be partially
attributed to delayed diagnosis and treatment.
Both primary and ATD-associated MPA showed a female
predisposition in children. The kidneys were the most
frequently involved organ, followed by the lungs. CNS
involvement was not rare among these pediatric patients,
especially those with ATD-associated MPA. The efficacy of
corticosteroid plus CTX treatment was evident in the
induction therapy for these patients. Early diagnosis, regular
followup, and optimized therapy are also important for
improving longterm outcomes.
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